GlassScriptPhysician profile
Matthew J Sanchez
NPI 1992187231
$1,266.59
in general payments reported to CMS, 2019-2025
17 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.85 · 2022: $43.47 · 2023: $445 · 2024: $358 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.34 | 2023-2025 | Vraylar |
| Corium, LLC | $218.35 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $129.36 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $87.35 | 2021-2023 | Rexulti |
| Alkermes, INC. | $66.83 | 2023-2024 | Lybalvi, Aristada, Vivitrol |
| Ironshore Pharmaceuticals INC. | $64.21 | 2024 | |
| Tris Pharma INC | $50.75 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $45.45 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $43.50 | 2024-2025 | Spravato |
| Lundbeck LLC | $42.12 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $38.77 | 2025 | Fanapt |
| Acadia Pharmaceuticals INC | $31.43 | 2023 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $22.54 | 2022 | |
| Avion Pharmaceuticals | $22.53 | 2023 | Methylphenidate Hydrochloride |
| Axsome Therapeutics, INC. | $21.48 | 2024 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $18.19 | 2024 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.39 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.